Cell 
Therapies+
  • Minaris Cell Therapies
  • Cell Banking
  • Technology Transfer
  • Cell Therapy Process & Analytical Development
  • Cell Therapy GMP Manufacturing
  • Cell Therapy Technologies
Viral 
Vectors+
  • Minaris Viral Vectors
  • Cell Banking
  • Technology Transfer
  • Viral Vector Process Development
  • Viral Vector GMP Manufacturing
  • Viral Vector Technologies+
    • Plasmid Engineering
    • TESSA® Technology
    • XOFLX® Cell Lines
Biologics &
CGT Testing+
  • Minaris Advanced Testing
  • Testing Services+
    • Testing Services Overview
    • Analytical Development
    • Assay Transfer
    • Biosafety Testing
    • Cell Line Characterization
    • Lot Release
    • Potency
    • Stability
    • Viral Clearance
  • Testing by Modality
  • Minaris Advanced Testing Facilities
  • Minaris Advanced Testing History
  • Submit a Sample
  • Testing Technologies+
    • AgentSCREEN™
    • Transmission Electron Microscopy (TEM)
Regulatory
& CMC+
  • Quality
  • Regulatory Support
About
Us+
  • The Minaris Story
  • Global Footprint for Local Manufacture
  • Leadership
  • News & Announcements
  • Events
  • Careers
Knowledge
Center
Contact Us

Enter a term to search

How are capital constraints impacting M&A and strategic partnerships in the CDMO and pharma sectors?

January 5, 2026

By Andy

Stay Connected with Minaris

Want the lastest insights on cell and gene therapy manufacturing and testing? Subscribe to receive updates, news and resources directly from our team.

Follow us on LinkedIn to stay updated on industry insights, innovations and company news.

Contact Us

  • 400 Rouse Boulevard,
    Philadelphia, PA 19112
  • +1-215-218-7100

© 2026 Minaris Advanced Therapies, LLC. All Rights Reserved.

  • Terms of Use
  • Privacy Policy
  • Data Policy
  • Cookies Policy